J&J Seeks Command Position In FcRn Space With Momenta Buyout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.

Johnson_and_Johnson
J&J will pay $6.5bn to buy out Momenta and its anti-FcRn candidate

Johnson & Johnson is looking to both take a lead position in a burgeoning area of the autoimmune therapy space and bolster its presence in the Boston-area biotech hub with its planned $6.5bn acquisition of Momenta Pharmaceuticals, Inc. Driving the deal announced 19 August is Momenta’s nipocalimab, a fully-human monoclonal antibody targeting neonatal Fc receptor (FcRn), which is in Phase II in multiple autoantibody-driven diseases.

It’s a remarkable turnaround for Momenta, which reduced its workforce in 2018 to de-emphasize biosimilar development and focus instead on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.